Alder BioPharmaceuticals (NASDAQ: [[ticker:ALDR]]) has appointed Paul Streck to serve as chief medical officer, a post he held at his former company, Insmed (NASDAQ: [[ticker:INSM]]). His experience also includes roles at GlaxoSmithKline (NYSE: [[ticker:GSK]]), Shire, and Amgen (NASDAQ: [[ticker:AMGN]]). Alder’s lead drug, eptinezumab, was developed to prevent migraine pain. The Bothell, WA-based company has said it expects to file for FDA approval in the first quarter of this year.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
